U.S. Transthyretin Amyloidosis Treatment Market is Growing Exponentially in Order to Gain More Demand by 2027

The U.S. transthyretin amyloidosis treatment market by Drug (Tafamidis, Diflunisal, Patisiran, Inotersen, and Others), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed), and Wild Type), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) is expected to be valued at US$ 36.9 million in 2018 and is projected to exhibit a CAGR of 52.4% over the forecast period (2018–2026). Unavailability of any alternative treatment options, expected drug launches in 2018, and rapid uptake of the newly available therapies are expected to drive U.S. transthyretin amyloidosis treatment market growth.

Get Sample Here

Patisiran received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) in 2017 for the treatment of hereditary ATTR (hATTR) amyloidosis with polyneuropathy. Furthermore, Alnylam Pharmaceuticals, Inc. filed a New Drug Application (NDA) for Patisiran in November 2017, and the firm reported that the NDA had been accepted by the US Food and Drug Administration (FDA) and that Patisiran had been given priority review status. Manufacturers are working hard to create new medicines for transthyretin amyloidosis treatment. There is no therapy for transthyretin amyloidosis in the United States, which is projected to provide lucrative prospects for manufacturers in the transthyretin amyloidosis market in the United States over the forecast period. The US Food and Drug Administration accepted Inotersen’s new drug application (NDA) for priority review in January 2018, setting a July 2018 deadline for the Prescription Drug User Fee Act (PDUFA), which was then pushed out to October 6, 2018. The introduction of Inotersen is expected to accelerate the growth of the transthyretin amyloidosis treatment market.

In order to launch their novel medicines into the market, key competitors in the industry are focusing on collaborations, acquisitions, and partnerships. For example, Akcea Therapeutics (an affiliate of Ionis Pharmaceuticals) is developing AKCEA-TTR-LRX, a Ligand Conjugated Antisense (LICA) that is planned to enter clinical trials in 2018 for the treatment of all kinds of ATTR amyloidosis. Ionis Pharmaceuticals finalised a previously announced agreement with its affiliate Akcea Therapeutics in March 2018 involving the global commercialization rights for Inotersen and AKCEA-TTR-LRX (given to Akcea Therapeutics). The medicine was created by Alnylam Pharmaceuticals, Inc. in partnership with Sanofi, and the Patisiran arrangement was reorganised in January 2018. Alnylam recovered global development and commercialization rights for its investigational RNAi therapies, including as Patisiran and ALN-TTRsc02, under the new agreement, while Sanofi resumed sole responsibility for Fitusiran development and commercialization (Hemophilia A and B).

Key Takeaways of the U.S. Transthyretin Amyloidosis Treatment Market:

• The U.S. transthyretin amyloidosis treatment market is expected to exhibit a CAGR of 52.4% over the forecast period (2018–2026), owing to product launches by manufacturers such as Alnylam Pharmaceuticals, Inc., and Ionis Therapeutics

• Patisiran (Alnylam Pharmaceuticals, Inc.) is currently ahead of its competitors in terms of approval and subsequent commercialization, and Alnylam may benefit from the first-mover advantage

• Therapies in the pipeline belong to the class of gene therapies (RNAi therapeutics and antisense drugs) which have the potential to cure the underlying cause of the disease

• Major players operating in the U.S. transthyretin amyloidosis treatment market include Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.

Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1919

U.S. Transthyretin Amyloidosis Treatment Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.

Main points in U.S. Transthyretin Amyloidosis Treatment Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global U.S. Transthyretin Amyloidosis Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: U.S. Transthyretin Amyloidosis Treatment Industry Impact

Chapter 2 Global U.S. Transthyretin Amyloidosis Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global U.S. Transthyretin Amyloidosis Treatment (Volume and Value) by Type
2.3 Global U.S. Transthyretin Amyloidosis Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global U.S. Transthyretin Amyloidosis Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America U.S. Transthyretin Amyloidosis Treatment Market Analysis
Chapter 6 East Asia U.S. Transthyretin Amyloidosis Treatment Market Analysis
Chapter 7 Europe U.S. Transthyretin Amyloidosis Treatment Market Analysis
Chapter 8 South Asia U.S. Transthyretin Amyloidosis Treatment Market Analysis
Chapter 9 Southeast Asia U.S. Transthyretin Amyloidosis Treatment Market Analysis
Chapter 10 Middle East U.S. Transthyretin Amyloidosis Treatment Market Analysis
Chapter 11 Africa U.S. Transthyretin Amyloidosis Treatment Market Analysis
Chapter 12 Oceania U.S. Transthyretin Amyloidosis Treatment Market Analysis
Chapter 13 South America U.S. Transthyretin Amyloidosis Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in U.S. Transthyretin Amyloidosis Treatment Business
Chapter 15 Global U.S. Transthyretin Amyloidosis Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com